# A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors

Source: https://onco.cc/trials/nct07767474/  
OnCo record `nct07767474` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ATX-898 run by Antares Therapeutics, Inc, now recruiting.

## Summary

A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07767474 by Antares Therapeutics, Inc, with 343 participants planned, started 2026-08-31. Conditions recorded: Advanced Solid Tumors. Interventions recorded: ATX-898, ATX-898, ATX-898, ATX-898, ATX-898, ATX-898, fulvestrant, ribociclib, ATX-898, fulvestrant, ribociclib and ATX-898, fulvestrant, ribociclib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07767474
- Phase: 1/2
- Setting: First-in-human Study of ATX-898, as Monotherapy and in Combination With Other Anti-neoplastic Agents, in Participants With Advanced Solid Tumors
- Sponsor: Antares Therapeutics, Inc
- Enrolled: 343

## Sources

- ClinicalTrials.gov NCT07767474: https://clinicaltrials.gov/study/NCT07767474

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [ATX-898](https://onco.cc/drugs/atx-898/)
- companies: [Antares Therapeutics](https://onco.cc/companies/antares-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07767474.json